CXCR4-Based Imaging Agents
Author:
Publisher
Society of Nuclear Medicine
Subject
Radiology, Nuclear Medicine and imaging
Reference38 articles.
1. CXCL12 (SDF-1)/CXCR4 Pathway in Cancer: Fig. 1.
2. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers
3. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus
4. Chemokines and Their Receptors: Drug Targets in Immunity and Inflammation
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Construction of CXCR4 Receptor-Targeted CuFeSe2 Nano Theranostic Platform and Its Application in MR/CT Dual Model Imaging and Photothermal Therapy;International Journal of Nanomedicine;2024-09
2. Chemokine receptor PET imaging: Bridging molecular insights with clinical applications;Nuclear Medicine and Biology;2024-07
3. LPA1-mediated inhibition of CXCR4 attenuates CXCL12-induced signaling and cell migration;Cell Communication and Signaling;2023-09-25
4. [68Ga]Ga‐PentixaFor: Development of a fully automated in hospital production on the Trasis miniAllinOne synthesizer;Journal of Labelled Compounds and Radiopharmaceuticals;2023-09-07
5. Small-Molecule Fluorescent Ligands for the CXCR4 Chemokine Receptor;Journal of Medicinal Chemistry;2023-03-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3